Ohio Board of Pharmacy issues emergency ruling banning most kratom products for 180 days - Ohio Capital Journal
Ohio Board of Pharmacy emergency ruling bans most kratom products for 180 days, effective immediately.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. All Ohio pharmacies (independent, retail chains, compounding, long-term-care) and any business selling kratom in Ohio. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate compliance required; enforcement begins upon ruling publication.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Most kratom products are now banned for 180 days under an emergency ruling by the Ohio Board of Pharmacy.
Who it affects
All Ohio pharmacies (independent, retail chains, compounding, long-term-care) and any business selling kratom in Ohio.
What you must do
Immediately stop selling, dispensing, or distributing banned kratom products; remove them from shelves and online listings.
Deadline
Immediate compliance required; enforcement begins upon ruling publication.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order